A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.

Bardelas, Jose; Figliomeni, Maria; Kianifard, Farid; Meng, Xiangyi

Bardelas, Jose; Figliomeni, Maria; Kianifard, Farid; Meng, Xiangyi.

Affiliation

Bardelas J; Allergy and Asthma Center of North Carolina, PA, Greensboro, NC 27401-1310, USA. j.bardelas@northstate.net

J Asthma ; 49(2): 144-52, 2012 Mar.

Article in En | MEDLINE | ID: mdl-22277052

Subject(s)

Anti-Asthmatic Agents/therapeutic use; Antibodies, Anti-Idiotypic/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Asthma/drug therapy; Adult; Antibodies, Anti-Idiotypic/adverse effects; Antibodies, Monoclonal, Humanized/adverse effects; Asthma/physiopathology; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Omalizumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Asthma / Antibodies, Anti-Idiotypic / Anti-Asthmatic Agents / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Asthma Year: 2012 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google